Intensity Therapeutics (INTS) Expected to Announce Quarterly Earnings on Tuesday

Intensity Therapeutics (NASDAQ:INTS) is projected to issue its Q1 2026 results before the market opens on Tuesday, May 12th. Analysts expect the company to announce earnings of ($1.0850) per share for the quarter. Parties can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Thursday, May 14, 2026 at 4:00 PM ET.

Intensity Therapeutics (NASDAQ:INTS) last announced its earnings results on Friday, March 27th. The company reported ($0.31) earnings per share (EPS) for the quarter. On average, analysts expect Intensity Therapeutics to post $-5 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Intensity Therapeutics Stock Up 1.0%

Shares of NASDAQ:INTS traded up $0.05 during trading on Tuesday, hitting $5.25. The stock had a trading volume of 6,244 shares, compared to its average volume of 46,423. Intensity Therapeutics has a 12 month low of $4.63 and a 12 month high of $43.50. The company has a market capitalization of $13.91 million, a PE ratio of -0.33 and a beta of 2.94. The firm’s fifty day moving average is $6.17 and its 200 day moving average is $8.74. The company has a quick ratio of 5.92, a current ratio of 5.92 and a debt-to-equity ratio of 0.01.

Analyst Ratings Changes

INTS has been the subject of a number of analyst reports. Weiss Ratings lowered Intensity Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, April 24th. Freedom Capital raised Intensity Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday, March 30th. Finally, Wall Street Zen raised Intensity Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, April 4th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Intensity Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $37.50.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in INTS. Jane Street Group LLC bought a new position in Intensity Therapeutics during the 4th quarter valued at approximately $26,000. Corient Private Wealth LLC bought a new stake in shares of Intensity Therapeutics in the 4th quarter worth $41,000. State Street Corp increased its holdings in shares of Intensity Therapeutics by 839.3% in the 4th quarter. State Street Corp now owns 136,200 shares of the company’s stock worth $56,000 after purchasing an additional 121,700 shares in the last quarter. Finally, Geode Capital Management LLC increased its holdings in shares of Intensity Therapeutics by 77.8% in the 4th quarter. Geode Capital Management LLC now owns 460,248 shares of the company’s stock worth $189,000 after purchasing an additional 201,357 shares in the last quarter. Institutional investors own 3.74% of the company’s stock.

About Intensity Therapeutics

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.